Increased plasma levels of metalloproteinase-9 are associated with abdominal aortic aneurysms  by McMillan, William D. & Pearce, William H.
Increased plasma levels of 
metalloproteinase-9 are associated 
abdominal aortic aneurysms 
with 
William D. McMillan, MD, and William H. Pearce, MD, Chicago, Ill 
Purpose: Previous investigators have identified isease-specific elevations of metalloelas- 
tase-9 (MMP-9) in aneurysm tissue biopsies. We hypothesized that circulating MMP-9 
might also be elevated in patients with aneurysms. The purpose of this study was to 
compare plasma and aortic tissue MMP-9 levels in patients with infrarenal aneurysms 
(AAAs), patients with symptomatic aortoiliac occlusive disease (AOD), and healthy 
patients. 
Methods: A sandwich enzyme-linked immunosorbent assay was used to measure plasma 
MMP-9 in patients with AAA (n = 22; mean age, 72.7 years), with AOD (n = 9; mean 
age, 60.5 years), and without disease (n = 8; mean age, 35.3 years). The MMP-9 levels 
also were measured in 48-hour supernatants of organ culture tissue explants from 
patients with AAA (n = 10; mean age, 66.2 years) and AOD (n = 5; mean age, 50.4 
years) and organ donors (n = 7; mean age, 48.1 years). The results were reported as the 
mean ± the standard error of the mean and analyzed with analysis of variance with mul- 
tivariate regression. 
Results: The plasma MMP-9 levels were significantly higher in the patients with AAA 
(85.66 ng/mL ± 11.64) than in the patients with AOD (25.75 ng/mL ± 4.159; P< .001) 
or the healthy patients (13.16 ng/mL ± 1.94; P < .001). No significant difference in plas- 
ma MMP-9 levels between patients with AOD and healthy patients was identified. The 
patients with multiple aneurysms had significantly higher levels of plasma MMP-9 than 
did the patients with an isolated AAA (134.68 ng/mL ± 17.5 vs 71.03 ng/mL ± 10.7; P 
< .04). In organ culture, AAA and AOD tissue explants produced significantly higher lev- 
els of MMP-9 (3218.5 ng/gm ± 1115.2 and 1283.1 ng/gm ± 310.6 aortic tissue) than 
did disease-free explants (6.14 ng/gm ± 2.3 aortic tissue; P < .0001). No significant dif- 
ference in MMP-9 production between AAA and AOD explants was identified. 
Conclusion: Plasma MMP-9 levels are significantly higher in patients with AAA than in 
patients with AOD or in healthy volunteers. The patients with multiple aneurysms have 
higher levels than those patients with an isolated AAA. Organ culture studies suggest 
that diseased aortic tissue is the source of MMP-9. (J Vasc Surg 1999;29:122-9.) 
Clinicians have long sought a systemic marker for 
aortic aneurysmal disease. In the past decade, a 
number of investigators have measured breakdown 
products of collagen I and elastin 2 in the urine and 
serum of patients with known aortic aneurysms 
(AAAs) in an effort to identify a reliable marker. 
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Unfortunately, these studies were limited by the fact 
that only small amounts of  such products are 
released into the circulation and most of the degrad- 
ed protein remains insoluble within the aortic wall. 
On the other hand, the enzymes that are responsible 
for aortic collagen and elastin degradation, the 
metalloproteinases, are soluble proteins. In 1985, 
Brown et al3 recognized elevated levels of  an 
unidentified soluble metalloelastase in the serum of 
patients with AAA. To date, no other investigator 
has measured circulating levels of a specific metallo- 
proteinase in patients with aneurysms. Theoretically, 
a highly expressed soluble metalloproteinase could 
be continuously released into the systemic ircula- 
tion and be measurable in the plasma of patients 
with AAA. I f  present, the elevations in circulating 
levels could serve as a marker for the disease in 
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patients at risk (ie, those strong family histories) and 
might correlate with rapid aortic growth. 
Although there are extensive studies of metallo- 
proteinases in aortic tissue, 4-1° there is no study that 
compares circulating levels of  the metalloproteinases 
in patients with and without AAA. Of  all the metal- 
loproteinases a sociated with aortic aneurysms, met- 
alloproteinase-9 (MMP-9) is among the most rea- 
sonable nzymes to study. Previous reports from our 
laboratory and others show that MMP-9 is the prin- 
ciple elastase within the aneurysm wall and that 
increases in MMP-9 expression exceed those of  
other metalloproteinases.4,7,11,12 Therefore, we 
hypothesize that circulating MMP-9 levels are ele- 
vated in patients with AAA and that these elevations 
also are associated with elevations in MMP-9 pro- 
duction with aneurysmal tissue. The purpose of  this 
study is two-fold: 
1. To measure plasma MMP-9 levels in patients 
before elective aneurysm repair, in patients who 
are admitted for treatment of  symptomatic aor- 
toiliac occlusive disease (AOD), and in healthy 
volunteers; and 
2. To measure aortic tissue MMP-9 production by 
means of  biopsies obtained from patients who 
undergo aortic surgery for aneurysmal or occlu- 
sive disease and from healthy organ donors. 
METHODS 
Specimens. Two groups of patients were studied. 
First, plasma was obtained from 22 patients who were 
admitted for elective repair of AAAs, nine patients 
who were admitted for treatment of AOD, and eight 
healthy volunteers after informed consent in accor- 
dance with the Institutional Review Board of  
Northwestern University/McGaw Medical Center. In 
a second group of patients, aortic tissue samples were 
obtained at surgery 3 to 6 cm below the renal arteries 
in 10 patients with infrarenal aortic aneurysms and in 
five patients with AOD after informed consent in 
accordance with the Institutional Review Board of 
Northwestern University/McGaw Medical Center. 
Seven normal aortic tissue specimens were obtained 
through the Regional Organ Bank of Illinois from 
organ donors at the time of  tissue procurement. All 
the patients with a history of other known systemic 
inflammatory conditions (ie, rheumatoid arthritis, 
polymyalgia rheumatica, rteritis) or with inflamma- 
tory aneurysms were excluded from the study. 
Plasma metal loprote inase-9 enzyme- l inked 
immunosorbent  assay. Blood samples were col- 
lected from venipuncture in heparinized tubes from 
awake patients before surgery or angiography. 
Plasma was collected with centrifugation (1000 x g 
for 15 minutes) within 30 minutes of blood sample 
collection, and the plasma was stored at -80°C until 
use. A commercially available sandwich enzyme- 
linked immunosorbent assay (ELISA) kit that used a 
MMP-9 monoclonal antibody (Biotrak MMP-9 
Human ELISA System, Amersham Life Science, 
Buckinghamshire, United Kingdom) was used 
according to the instructions provided by the manu- 
facturer to determine plasma MMP-9 levels. 
Specimen MMP-9 levels were quantified via extrap- 
olation from a log-log linear regression curve of  
purified standards. All the samples were run in dupli- 
cate and averaged. If measured MMP-9 levels for an 
individual sample varied by greater than 10%, the 
sample was rerun in triplicate and the average value 
was taken. The plasma samples from the patients 
with aneurysms were routinely diluted 1:10, and the 
samples from patients with occlusive disease were 
diluted 1:2. The samples from the healthy volunteers 
were not diluted. The samples with MMP-9 levels 
outside of the linear range of the assay (0.5 to 32 
ng /mL)  were subsequently serially diluted, and the 
ELISA was repeated. The within-assay precision 
(<6%) and the between-assay precision (<10%) were 
determined by the manufacturer. The specificity of 
the MMP-9 ELISA as determined by the manufac- 
turer did not reveal cross reactivity with MMP-1, 
MMP-2, MMP-3, tissue inhibitor of the metallopro- 
teinases-1 (TIMP-1), or TIMP-2. The ELISA mea- 
sured all forms of MMP-9, including the MMP- 
9 /T IMP-  1 complex. 
Tissue explant supernatants. The 48-hour tis- 
sue supernatants from the operative specimens of 
AAA (n = 10) and AOD (n = 5) and from the disease- 
free specimens (n = 7) were collected and processed as 
previously described)334 Briefly, all the aortic speci- 
mens were washed with phosphate-buffered saline 
solution to remove the residual thrombus, minced, 
placed into 4 mL/gm of Roswell Park Memorial 
Institute media (Gibco BRL, Gaithersburg, Mo) with 
penicillin/streptomycin, a d incubated at 37°C with 
5% CO 2 for 48 hours. The supernatant then was 
removed, centrifuged, and stored at -80°C. The 
MMP-9 levels then were determined with the sand- 
wich ELISA as described above. Aneurysm super- 
natants routinely were diluted 1:50 to 1:100, occlu- 
sive specimen supernatants were diluted 1:20 to 1:50, 
and healthy aortic supernatants were not diluted. 
Data analysis. The results were reported as the 
mean + the standard error of  the mean and compared 
with analysis of the variance with a Tukey test to 
determine the differences between groups. For organ 
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Fig 1. Plasma metalloproteinase levels in patients with 
abdominal aortic aneurysms and with symptomatic aor- 
toiliac occlusive disease and in healthy volunteers. 
Metalloproteinase-9 levels were significantly higher in 
patients with aneurysms (P < .001) than in patients with 
occlusive disease or in healthy volunteers. There was no 
significant difference between occlusives and normals. 
Values are expressed as mean + standard error of mean and 
compared with analysis of variance with Tukey test. 
MMP-9, Metalloproteinase-9; AAA, abdominal aortic 
aneurysm; AOD, aortoiliac occlusive disease; NA, healthy 
volunteer. 
culture levels, data were logarithmically transformed 
before the analysis because of non-normal distribu- 
tion of values. Multivariate regression analysis was 
used to test for disease characteristics (AAA diameter, 
presence of other aneurysms) and patient characteris- 
tics (family history of AAA, age, sex, smoking) asso- 
ciated with higher MMP-9 plasma levels. 
RESULTS 
Plasma metalloproteinase-9 levels. Plasma 
MMP-9 levels were assayed in 22 patients with 
aneurysms, in nine patients with AOD, and in eight 
healthy volunteers. The characteristics of each group 
are listed in Table I. The plasma MMP-9 levels were 
significantly higher in the patients with aneurysms 
(85.66 ng /mL _+ 11.64; range, 21.2 to 203.8 
ng /mL)  than in the patients with AOD (25.75 
ng /mL +_ 4.159; range, 7.9 to 30.5 ng /mL;  P < 
.001) or in the healthy volunteers (13.16 ng /mL _+ 
1.94; range, 7.1 to 21.1; P < .001). There was no 
significant difference identified in the plasma MMP- 
9 levels between the patients with AOD and the 
healthy volunteers (Fig 1). 
Multivariate regression analysis of all the patients 
(healthy and with AAA and AOD) with regard to 
age, sex, smoking, hypertension, and combinations 
of these factors showed no significant correlation 
with plasma MMP-9 levels. On the other hand, sub- 
group analysis of  the patients with aneurysms 
showed significant positive correlation between 
plasma MMP-9 levels and the presence of more 
than one aneurysm (P < .005), significant negative 
correlations between the age of the patient with 
an aneurysm (P < .04) and the diameter of the 
aneurysm present (P < .05), and no significant cor- 
relation with regard to sex or family history of 
aneurysm disease. However, when multivariate 
analysis was applied to all the significant associations 
in the aneurysm subgroup, only the association 
between the presence of multiple aneurysms and 
higher plasma MMP-9 levels remained significant 
(134.68 _+ 17.51 ug /mL vs 71.03 _+ 10.73 ug/mL;  
P < .04; Table II). 
Tissue explant supernatants. MMP-9 levels 
were assayed in 48-hour supernatants of tissue 
explants from 10 aneurysms, five aortas with ather- 
osclerotic occlusive disease, and seven healthy aor- 
tas. The patient characteristics of each group are list- 
ed in Table I. At 48 hours, the aneurysm tissue 
explants produced significantly higher levels of 
MMP-9 (3218.5 ng /gm + 1115.2 aortic tissue; 
range, 462 to 10,891 ng/gm) than did the explants 
from the healthy aorta (6.14 ng /gm + 2.3 aortic tis- 
sue; range, 4.4 to 22.1 ng /gm;  P < .001). The 
occlusive tissue explants likewise produced signifi- 
cantly higher levels of MMP-9 (1283.1 ng /gm + 
310.6 aortic tissue; range, 836 to 2480 ng/gm; P < 
.001) than did normal aortic tissue. However, there 
was no significant difference in MMP-9 production 
between aneurysm and occlusive aortic tissue 
explants (Fig 2). 
D ISCUSSION 
Aortic aneurysms are associated with a marked 
inflammatory infiltrate and evidence of extensive tis- 
sue remodeling. 1~-18 Although the factors that initi- 
ate the formation of the aneurysm are unknown, 
extensive data exist that detail the complexities and 
mechanisms responsible for aortic wall remodeling. 
In particular, aortic aneurysms have been found to 
have increased levels of several members of the met- 
alloproteinase family (MMP-1, MMP-2, MMP-3, 
MMP-9). 4-1° These metalloproteinases are impor- 
tant for degradation of the extracellular matrix and 
weakening of the arterial wall with destruction of 
both collagen and elastin. Interestingly, the same 
metalloproteinases areimportant in matrix remodel- 
ing in rheumatoid arthritis and in the spread of 
metastatic cancer cells.19, 20 In both of these diseases, 
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Fig 2. Results of metalloproteinase-9 nzyme-linked immunosorbent assay on 48-hour super- 
natants from aortic tissue explants. Values were transformed tonatural log because of non-nor- 
real distribution of data. Aneurysm and occlusive aortic specimens produced significantly more 
metalloproteinase-9 than did healthy aortic tissue. No significant difference was identified 
between aneurysm and occlusive specimens. 
MMP-9, Metalloproteinase-9; AAA, abdominal aortic aneurysm; AOD, aortoiliac occlusive 
disease; normal, healthy volunteer. 
Table I. Patient characteristics 
AAA plasma Occlusive plasma Healthy plasma AAA tissue Occlusive tissue Healthy tissue 
(n = 22) (n = 9) (n = 8) (n = 10) (n = 5) (n = 7) 
Age (years) 72.7 60.5 35.3 66.2 50.4 48 
Sex (M:F) 16:6 7:2 7:1 8:2 4:1 6:2 
Hypertension (%) 91 100 0 80% 100% 0% 
Smoking (%) 69 71 13 70% 80% 38% 
Diabetes (%) 11 44 0 20% 40% 0% 
AAA, Abdominal aortic aneurysm. 
plasma MMP-9 has been used as a marker for the 
state of  the disease, and in the case of  cancer, to 
detect the presence of  occult metastases.Z1, 22 
Because MMP-9 appears to be an important com- 
ponent of  the recently described enzyme system 
responsible for aortic aneurysm formation, it seemed 
only logical to study circulating plasma levels of  this 
metalloproteinase. In our study, we found that the 
plasma levels of MMP-9 were significantly elevated 
in patients with aneurysms, and particularly in those 
patients with multiple aneurysms, as compared with 
patients with AOD or with healthy volunteers. 
The source of the plasma MMP-9 appears to be 
the diseased aortic wall. In fact, our organ culture 
data showed that both aneurysm tissue and occlusive 
tissue in culture produced between 100 and 1000 
times more MMP-9 than did healthy specimens. 
Our tissue data are in agreement with previous 
reports from our own laboratory and others that 
describe elevations in MMP-9 messenger RNA and 
protein levels in aneurysmal and occlusive tissue 
biopsies.S, 12 Studies that use in situ hybridization 
show that MMP-9 is produced by inflammatory cells 
in both aneurysmal and occlusive tissue sec- 
tions.8,10,23, 24 Although the aortic tissue in this 
study was not examined histologically, it may be 
assumed that inflammation was present in explants 
from both AAA and AOD. However, the striking 
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Table I I .  Regression analysis of 22 patients with aneurysms 
Univariate coefficient Univariate mean 
Source Univariate P value (continuous variable) (affected vs unaffected) Multivariate P value 
Age 0.032 -2.14 NA .23 (NS) 
Other aneurysm 0.006 NA 134.68 vs 71.03 0.033 
Diameter 0.049 -18.12 NA .35 (NS) 
difference in the plasma levels of MMP-9 in patients 
with AAA as compared with AOD stands in appar- 
ent contrast o the absence of such a difference in 
our organ culture data. This difference (plasma val- 
ues vs tissue culture) probably reflects the greater 
amount of  diseased aortic wall present in patients 
with AAA as compared with patients with AOD. 
This notion is further supported by the finding that 
patients with multiple aneurysms have higher levels 
than those patients with single aneurysms. 
Reports by Powell and others have shown that 
aneurysms may have varying amounts of particular 
metalloproteinases on the basis of  their size.9, 25 
Previous tissue studies show that small aneurysms 
appear to have greater levels of MMP-2 as compared 
with MMP-9.  In the midrange, 4-cm to 5-cm 
aneurysrns, MMP-9 reaches apeak but later declines 
with greater enlargement, possibly as a result of  burn 
out of  the inflammation within the arterial wall. 
Although univariate analysis of plasma levels in our 
study shows a similar trend (ie, a significant negative 
correlation between plasma MMP-9 level and 
aneurysm diameter), a wide range of aneurysm size 
was not available for comparison. Furthermore, it
may be that the plasma level does not bear a direct 
relationship with the size of the aneurysm but rather 
with the extent of aneurysm. Aneurysms are known 
for their expansion into the aortoiliac segment, and 
plasma levels may correlate more directly with the 
morphology than the absolute diameter of the AAA. 
Atherosclerosis and other inf lammatory states 
are associated with nonspecific markers of inflamma- 
tion. 26 The data presented here regarding MMP-9 
may, in part, be a reflection of a similar proinflam- 
matory response. However, in this preliminary 
study, it seems clear that MMP-9 is associated with 
aneurysmal disease and that its origin is most likely 
the arterial wall. Although this study is only a single 
glimpse of  plasma MMP-9 levels in patients who 
undergo surgical or radiologic intervention, it will 
be important to study patients who are observed for 
small aneurysms. Abrupt changes in plasma MMP-9 
levels may signal rapid aneurysm expansion, which 
supports the hypothesis, that the metalloproteinase 
profile changes with aneurysm size. It  has been long 
assumed that the propensity of aneurysms to rupture 
is on the basis of diameter, but changes in the biol- 
ogy of the arterial wall (ie, changes in the MMP-9 
levels) may play a greater ole in the rate of rupture 
than Laplace's law. 
In summary, the results of this study show that 
MMP-9 levels are significantly elevated in patients 
with AAAs as compared with patients with sympto- 
matic aortic occlusive disease or with healthy volun- 
teers. Patients with multiple aneurysms have higher 
circulating levels of MMP-9 than do patients with 
isolated infrarenal aortic aneurysms. Future longitu- 
dinal studies with a large number of patients are nec- 
essary to test the clinical value of MMP-9 as an inde- 
pendent marker of aneurysmal disease and to identi- 
fy patients at risk for rapid expansion of  their 
aneurysms. In addition, it will be important to study 
circulating levels of  MMP-9 in patients after 
endovascular t eatment of their aneurysms and in 
patients after surgery. Similar to other markers for 
cancer, such as carotid endarterectomy, the reap- 
pearance of this enzyme in the peripheral circulation 
could signal the development of  a recurrent 
aneurysm. 
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D ISCUSSION 
Dr  Rober t  W. Thompson (St Louis, Mo). Abdominal 
aortic aneurysms are associated with chronic inflammation 
and connective tissue destruction. It is now almost estab- 
lished dogma that matrix metalloproteinases participate in 
the pathogenesis of  aneurysm disease. MMP-9 is one of  
18 different matrix metalloproteinases, but it is of  partic- 
ular interest in aneurysms for the following reasons: (1) it 
is an inducible product of  macrophages that are prevalent 
within aneurysm tissues; (2) it is one of  only four MMPs 
capable of  degrading elastin fibers, at least in vitro; and (3) 
it is produced in large amounts in human and experimen- 
tal abdominal aortic aneurysms. Drs McMillan and Pearce 
have now begun to address another dimension of  this 
problem by examining whether the production of  MMP- 
9 in aneurysms i  high enough to result in elevated circu- 
lating levels. I think this paper will be remembered 
because it shows for the first time that plasma MMP-9 is 
convincingly elevated in patients with aneurysms as com- 
pared with appropriate controls. This initially does not 
appear to be particularly surprising; however, it has impor- 
tant implications for further investigation. 
First, the authors suggest that elevated plasma levels of  
MMP-9 are derived from the aneurysm itself. They base 
this conclusion on studies in organ culture. Their results 
are remarkably similar to those we reported 3 years ago in 
the Journal of  Clinical Investigation, with a similar 
enzyme-linked immunosorbent assay for MMP-9. On the 
other hand, MMP-9 is normally present in plasma and it is 
produced in many other tissues, including atherosclerotic 
plaques. And it is increased in the plasma in diseases asso- 
ciated with chronic inflammation, particularly rheumatoid 
arthritis and cancers of  the breast and gastrointestinal 
tract. Speculation as to the source of  circulating MMP-9 
must therefore be interpreted with some degree of can- 
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tion. If the aneurysm was indeed the source of circulating 
MMP-9 in these patients, one would predict hat plasma 
MMP-9 levels would fall after aneurysm repair. Because 
this would provide more convincing evidence, have the 
authors taken the opportunity o remeasure plasma MMP- 
9 after surgical repair? And, if so, did they observe the 
expected ecrease that they might have found? 
My second question arises from the suggestion that 
plasma MMP-9 might be used as a screening test to deter- 
mine which patients might be prone to the development 
of aortic aneurysms. I wonder whether there is really a 
need for such a test. We are already aware of many clinical 
factors that raise susceptibility o aneurysm disease, partic- 
ularly age more than 65 years, atherosclerosis, and smok- 
ing. Six percent o 9% of the population with these risk 
factors will be found to have an aortic aneurysm with 
ultrasound scan screening. Abdominal ultrasound scan- 
ning is clearly more accurate in determining whether an 
aneurysm is present, and my suspicion is that a plasma 
enzyme-linked immunosorbent assay for MMP-9 is not 
going to be all that different in cost than an ultrasound 
scan when used as a population screening test. It is also 
unclear how one might deal with the fact that MMP-9 lev- 
els are elevated in a number of other diseases. Can the 
authors peculate on the potential cost of a plasma MMP- 
9 enzyme-linked immunosorbent assay measurement and 
discuss how one would evaluate a patient's levels with a 
positive blood test but no abdominal aleurysm with ultra- 
sound scan? 
Additional concerns in using plasma MMP-9 for screen- 
ing are that the number of patients in this study was rela- 
tively small compared with other studies on plasma MMP- 
9 in other conditions and that the mean age of the control 
group was less than the age in the aneurysm group. Also, 
this study does not provide vidence that MMP-9 is elevat- 
ed either before the development or early in the develop- 
ment of aortic aneurysms nor does it show that MMP-9 
actually plays a direct role in causing aneurysmal degenera- 
tion. Like other proteins, plasma MMP-9 levels are simply 
elevated in the patients with established aneurysms. 
Circulating levels of tumor necrosing factor-~, interleukin- 
1, ~/-interferon, and, most particularly, the aminoterminal 
propeptide of type III procollagen also are markedly elevat- 
ed in these patients. These are all markers of chronic inflam- 
mation and accelerated connective tissue metabolism. I 
wonder whether the authors have had a chance to examine 
how the plasma levels of MMP-9 compare with these other 
types of circulating markers of inflammation. 
Finally, I think the real reason this study is so important 
can actually be drawn from the paper by Dr Bigatel and col- 
leagues. For example, as we begin to decipher the mecha- 
nisms responsible for aneurysm growth and as this knowl- 
edge becomes translated into new pharmacologic strategies 
for small aortic aneurysms, there will be an increasing need 
for simple assays to monitor the patient's response to thera- 
py. If MMP-9 is derived from the aneurysm wall and if it is 
elevated in patients with small aortic aneurysms, assays like 
this might provide a valuable way to monitor disease activity 
in patients who are treated with drugs like doxycycline and 
other metalloproteinase inhibitors rather than depend solely 
on ultrasound scan examination at 6-month to 12-month 
intervals. In this light, my final question is whether the 
authors have measured plasma MMP-9 levels in patients 
with small aortic aneurysms and have they observed any 
changes in the patients who have been followed without sttr- 
gicai repair, especially during gradual aneurysm expansion? 
I think we all look forward to further studies on this 
problem, and I thank the Society for the opportunity to 
discuss this intriguing paper. 
Dr William D. McMiUan (Chicago, Ill). Thank you, 
Dr Thompson, for those insightful comments. 
I did have one slide prepared because I anticipated one 
question about whether or not the levels fell after the 
patients underwent repair. This really represents prelimi- 
nary data that I have only collected on five of the 22 
patients in the initial study. But one gets the idea that, in 
each of these five patients, each of the levels fell, and, in 
fact, each returned to the normal range. And so, I feel 
somewhat cautiously optimistic that the levels will return 
to normal after repair, which indicates in some way, albeit 
it somewhat superficially, that the aneurysm ay be the 
source of the enzyme in the bloodstream. 
The second question asked was whether or not this 
was really going to work out as a screening test. I would 
try to say that our point in doing this work was not to 
advocate it as a screening test for aneurysms. There are a 
variety of other issues involved in that. 
How much does it cost? I can tell you that the 
enzyme-linked immunosorbent assay kit costs $500 and 
that you can examine about six patients on a single kit. 
Certainly, the cost would be lessened if the examination 
were done in large scale, but I do not really have a handle 
on whether or not it would be cost effective as compared 
with an ultrasound scan. 
In terms of the longitudinal evaluation of patients, it is 
intriguing to wonder whether or not, if you followed a 
patient with a small aneurysm, an elevated MMP-9 level 
would signal a more rapid expansion rate. And certainly 
that would be one of our long-term goals in measuring 
this enzyme. I think that, as Dr Thompson correctly 
pointed out, the screening of large populations with this 
blood test may not be where this is headed at all. On the 
other hand, it may be possible to find more clinically rele- 
vant correlations with expansion rate or degree of inflam- 
mation with the MMP-9 levels. 
Finally, with regards to the other studies that are out 
there in terms of markers for aneurysm disease, I like our 
study a little better, not because I doubt the data of the 
other authors, but because mechanically this makes more 
sense to me. The MMP-9 is a potential degradative 
enzyme that can cause aneurysms at least in experimental 
models. And the fact that it goes away with the repair of 
the aneurysm is again suggestive that it actually does com e 
from the aneurysm. 
We do not have data about levels in patients with small 
aneurysms who have been followed longitudinally. 
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Dr B. Timothy Baxter (Omaha, Neb). Congranalations 
on your study. My question is, Have you considered the 
possibility that the high MMP-9 levels were related to 
thrombus in the aneurysm? Did you correlate this with 
thrombus to see if that was a possibility? 
Dr McMillan. I did do that about a month and a half 
ago. I went back and looked at as many computed tomo- 
graphic scans as I could find of these patients, and I did 
not find a correlation that was significant between the 
amount of thrombus. Now, again, we are dealing with a 
relatively small number of patients and I did not have all 
the computed tomographic scans available to make that 
determination. 
Dr Glenn C. Hunter  (Galveston, Tex). I enjoyed your 
paper. I have a couple of questions. One relates to your 
control group. I assume these specimens were obtained 
from transplant donors who receive numerous medica- 
tions and preservation solutions that may potentially influ- 
ence your assay. I wonder, therefore, how certain you are 
that the controls do not express MMPs in organ culture? 
Secondly, have you examined these same specimens 
histologically to assess the degree of inflammation present? 
If you postulate that the aorta is producing the MMPs, 
then there should be a large number of inflammatory cells 
in the tissue. 
Dr McMillan. As to the first question about the con- 
trol group and the tissue studies, we go to the actual organ 
harvest to obtain these and get them out of the patient as 
soon as possible, during the time that the kidneys and liver 
and pancreas are harvested. So, as best as we can, we try 
to avoid long delays from the procurement to our actual 
analysis of the tissue. 
As to the second question, we and others have looked 
in previous tudies at the amount of inflammation within 
the aortic wall and have found that the aneurysms have 
higher inflammatory scores and higher levels of MMP-9 in 
their wall. We did not repeat hat in this study, and, there- 
fore, I have to answer that from previously published ata. 
Dr William H. Baker (Maywood, Ill). This was a very 
nice paper. The Northwestern group has had a unique 
opportunity to follow patients who have undergone 
endovascular repair. Have you done so with this tech- 
nique? 
Dr McMillan. Yes, we are trying to do that. I have, like 
a vampire, collected five specimens from patients who have 
undergone ndovascular repair and have gotten two of 
them back in follow-up examination. Both of the levels 
fell, but I cannot correlate beyond that. And certainly that 
is something that will be interesting to see, whether the 
patient with a continually expanding aneurysm or one that 
does not shrink has an elevated level as compared with a 
patient who has a completely excluded and shrinking 
aneurysm. 
Dr Wiley F. Barker (Los Angeles, Calif). To clarify 
that last point, your last slide indicated this fall in levels of 
MMP-9 after treatment of the aneurysms. Were those 
aneurysms treated with complete xcision or not? 
Dr McMillan. There were five patients. Three of them 
underwent treatment with actual open repair with a graft 
placed, and two of them underwent reatment by 
endovascular means. 
Dr Christopher K. Zarins (Stanford, Calif). The fact 
that you found elevated MMP-9 levels in both aneurysmal 
and occlusive tissue is interesting. Does that allow you to 
address the age-old question on the pathogenesis of 
aneurysms? Is it related to atherosclerosis? 
Dr McMillan. I believe that it does not give me a 
license to address that question conclusively. My personal 
feeling is that it is related to atherosclerosis, but beyond 
that I cannot give you a strong answer. 
